Search

Your search keyword '"Zijlstra J"' showing total 898 results

Search Constraints

Start Over You searched for: Author "Zijlstra J" Remove constraint Author: "Zijlstra J"
898 results on '"Zijlstra J"'

Search Results

1. Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma: results from the randomized international GHSG HD18 trial

2. Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma

5. Cost-utility of an eHealth application ‘Oncokompas’ that supports cancer survivors in self-management: results of a randomised controlled trial

6. Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma: results from the randomized international GHSG HD18 trial

7. R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study

10. Risk of male breast cancer after Hodgkin lymphoma

12. Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP

14. Reproducibility of FDG PET-CT liver SUV uptake metrics as reference or normalisation factor

15. OS03.6.A Rituximab in primary CNS lymphoma - long term follow-up of the phase III HOVON 105/ALLG NHL 24 Study

16. The challenges and possibilities of public access defibrillation

17. ESICM LIVES 2016: part two: Milan, Italy. 1–5 October 2016

19. P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY

20. S203: ABSCOPAL EFFECT OF RADIOTHERAPY AND NIVOLUMAB IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: PRE-PLANNED INTERIM ANALYSIS OF THE INTERNATIONAL GHSG PHASE II AERN TRIAL

21. P1254: RESPONSE TO DA-EPOCH-R IN PATIENTS WITH HIGH GRADE B CELL LYMPHOMA IS ASSOCIATED WITH A REDUCTION OF PD1 POSITIVE EXHAUSTED CD8 T CELLS

25. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study

27. Glucocorticosteroids for sepsis: systematic review with meta-analysis and trial sequential analysis

34. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

37. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

40. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

42. LONG‐TERM FOLLOW‐UP AND BIOMARKER ANALYSES OF BRENTUXIMAB VEDOTIN AND DHAP IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS: THE HOVON/LLPC TRANSPLANT BRAVE STUDY

43. PREDICTIVE VALUE OF QUANTITATIVE 18F‐FDG‐PET‐CT RADIOMICS ANALYSIS IN 174 PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA

44. POS0809 A BIOMARKER PROFILE AIDING AN EARLY DIAGNOSIS OF GIANT CELL ARTERITIS

46. Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients

49. F-18-FDG PET/CT baseline radiomics features are predictive of outcome in diffuse large B-cell lymphoma patients

50. Aberrant patterns of PET-CT response for diffuse large B-cell lymphoma patients with MYC rearrangement

Catalog

Books, media, physical & digital resources